
Medpace (MEDP) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Medpace in October 2026.
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.
Medpace (MEDP) Stock Forecast
Analyst price target, next 12 months
$523.58
-15.4% vs today's $619.10
Price range over the last 12 months
Close to its 12-month high
Analysts covering Medpace have a consensus 12-month target of $523.58, below the current price of $619.10.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 6 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest maintaining current shares of Medpace, with a target price of $523.58.
Financial Health
Medpace is performing well with strong revenue and cash flow, indicating healthy financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.